SEC Form 10-Q filed by Kalaris Therapeutics Inc.
$KLRS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/23/2025 | $19.00 | Buy | Chardan Capital Markets |
| 11/3/2025 | $20.00 | Mkt Outperform | Citizens JMP |
| 9/3/2025 | $23.00 | Strong Buy | Raymond James |
| 7/23/2025 | $3.00 | Neutral | Piper Sandler |
| 5/7/2025 | $20.00 | Outperform | Leerink Partners |
| 4/8/2025 | Outperform | William Blair |
BERKELEY HEIGHTS, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company developing differentiated therapies for retinal diseases, today announced that clinical data from its Phase 1 study of TH103 will be presented at the 49th Annual Meeting of the Macula Society, taking place February 25-28 in San Diego, California. TH103 is a novel investigational therapy engineered by VEGF scientific pioneer Dr. Napoleone Ferrara to achieve enhanced VEGF inhibition and increased intraocular retention. The presentation will include safety, tolerability, pharmacokinetics and early efficacy outcomes following intravitreal a
BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell securities in a private placement for aggregate gross proceeds of approximately $50.0 million, before deducting placement agent fees and other offering expenses. The private placement includes participation from both new and existing investors, including ADAR1 Capital Management, Coastlands Capital, Invus
TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection TH103 was generally well tolerated, supporting further dose escalation beyond 2.5 mg TH103 showed a 27 to 51-fold lower plasma Cmax by pharmacokinetic analysis compared with current leading agents, indicative of increased intraocular retention Accelerating enrollment in ongoing Phase 1b/2 multi ascending dose-finding study; preliminary efficacy and safety data expected 2H 2026 Kalaris conference call today at 4:30 pm EST BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS), a clinical-stage biopharmaceutical c
SCHEDULE 13D/A - Kalaris Therapeutics, Inc. (0001754068) (Subject)
8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
3 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
Chardan Capital Markets initiated coverage of Kalaris Therapeutics with a rating of Buy and set a new price target of $19.00
Citizens JMP initiated coverage of Kalaris Therapeutics with a rating of Mkt Outperform and set a new price target of $20.00
Raymond James initiated coverage of Kalaris Therapeutics with a rating of Strong Buy and set a new price target of $23.00
TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection TH103 was generally well tolerated, supporting further dose escalation beyond 2.5 mg TH103 showed a 27 to 51-fold lower plasma Cmax by pharmacokinetic analysis compared with current leading agents, indicative of increased intraocular retention Accelerating enrollment in ongoing Phase 1b/2 multi ascending dose-finding study; preliminary efficacy and safety data expected 2H 2026 Kalaris conference call today at 4:30 pm EST BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS), a clinical-stage biopharmaceutical c